Heart failure & cardiomyopathiesSecondary analysis
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
- Secondary analysis of the FINEARTS-HF randomised trial
- prespecified analysis
Authors' conclusion
In patients with HFmrEF/HFpEF, the beneficial effects of finerenone on clinical events and symptoms were consistent, regardless of COPD status.
Study context
- Population
- Patients with heart failure (HF) with mildly reduced or preserved EF (HFmrEF/HFpEF), with or without investigator-reported chronic obstructive pulmonary disease (COPD)773 (12.9%) with COPD
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo, by COPD status
- Primary endpoint
- Composite of:
- CV death
- Total worsening HF events
Primary result
As reported in the abstract
CV death and total worsening HF events, by COPD status (subgroups)
Finerenone vs PlaceboRelative risk (95% CI)
no COPD
0.84(0.73–0.97)
COPD
0.84(0.61–1.16)
Secondary outcomes
| Outcome | adjusted rate ratio (95% CI) | |
|---|---|---|
| Primary endpoint, COPD vs no COPD (prognosis) | 1.44 (1.21–1.71) | |
| 0.512Adjusted rate ratio (log scale) |
All secondary outcomes
- Consistent effects irrespective of COPD status
Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score · baseline to 12 months
- Finerenone improved score to a similar extent with and without COPD
- P for interaction = 0.46
Original publication
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Eur J Heart Fail. Published 13 April 2025. doi:10.1002/ejhf.3661
Summarised from the published abstract; every number is checked against it